Exiqon A/S has announced the launch of its XploreRNA™ app for advanced cross-database searches, easy interpretation of data and seamless planning of experiments.
XploreRNA™ allows scientists engaged in transcription analysis to scroll any transcript, view splice sites, SNPs, and to zoom in on specific transcripts of interest in an interactive interface. Major databases including Ensembl, miRBase etc., have been cross-annotated to provide for all-in-one searches. Relevant abstracts and original publications have been integrated through PubMed. Products are automatically customized to address search results and readily ordered.
The body of biological data is growing exponentially which makes it challenging for scientists to stay abreast and benefit from big data. To complicate matters different annotations of major databases make cross-database searches time consuming and complicate the identification of relevant genetic information, e.g. microRNA-mRNA interactions. XploreRNA™ overcomes all of these challenges, and is the first in a series of new apps from Exiqon for scientists in both academia and industry.
XploreRNA™ enables “on-the-fly” discussions based on cross-annotated scientific information that is now made available at users fingertips. Results may be easily shared and converted to studies of relevant gene expressions whether for validation purposes or functional analysis.
“An important value proposition for Exiqon is to guide our customers through experimental data, to reach scientific conclusions and make decisions on how to validate data. The XploreRNA™ app does all of this for our customers and requires no prior knowledge about complicated database searches” says Henrik M. Pfundheller, SVP, Sales and Marketing and continues “Should our customers be interested in conducting further experiments the XploreRNA™ will suggest the relevant customized LNA® enhanced products directly available for ordering”.
XploreRNA™ is currently available on iOS platforms but will soon also be available on Android and Windows platforms.